AI Article Synopsis

  • The use of GLP-1 agonists like semaglutide is rising for weight loss and managing non-alcoholic steatohepatitis (NASH), but safety data for NASH cirrhotic patients is limited.
  • A documented case showed a patient with NASH-cirrhosis experienced liver decompensation after rapid weight loss on semaglutide, leading to the need for liver transplant waitlisting.
  • Following the cessation of semaglutide and nutritional support, the patient's condition improved, allowing her to be removed from the transplant list, emphasizing the importance of caution and further research in treating cirrhotic patients with these medications.

Article Abstract

There is rapidly increasing uptake of GLP-1 (glucagon-like peptide-1) agonists such as semaglutide worldwide for weight loss and management of non-alcoholic steatohepatitis (NASH). remains a paucity of safety data in the vulnerable NASH cirrhotic population. We report herein the first documented case of liver decompensation and need for liver transplant waitlisting in a patient with NASH-cirrhosis treated with semaglutide. Rapid weight loss led to the development of ascites and hepatic encephalopathy and an increase in the patients Model for Endstage Liver Disease-Na (MELD-Na) score from 11 to 22. Aggressive nutritional supplementation was commenced and the semaglutide was stopped. Over the following months she regained her weight and her liver recompensated and her MELD-Na decreased to 13, allowing her to be delisted from the transplant waitlist. This case serves as a cautionary tale to clinicians using semaglutide in the cirrhotic population and highlights the need for more safety data in this patient group.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10768411PMC
http://dx.doi.org/10.3748/wjg.v29.i47.6165DOI Listing

Publication Analysis

Top Keywords

weight loss
12
liver decompensation
8
rapid weight
8
non-alcoholic steatohepatitis
8
safety data
8
cirrhotic population
8
liver
5
semaglutide
5
decompensation rapid
4
weight
4

Similar Publications

Dihydroartemisinin ameliorates skeletal muscle atrophy in the lung cancer cachexia mouse model.

J Cancer Res Ther

December 2024

Department of Medical Ultrasound, Shandong Provincial Qianfoshan Hospital, Shandong University, Jinan, Shandong, People's Republic of China.

Introduction: Cancer cachexia (CC) is characterized by weight loss with specifically reduced skeletal muscles and adipose tissues in patients with late-stage cancer. Dihydroartemisinin (DHA), an effective antimalarial derivative of artemisinin, has been demonstrated to have anti-inflammatory and antitumor properties.

Materials And Methods: This study examined the effects of DHA on the Lewis lung carcinoma (LLC)-induced CC mouse model.

View Article and Find Full Text PDF

Physical activity improves myocardial structure, function and resilience via complex, incompletely defined mechanisms. We explored effects of 1-2 wks swim training on cardiac and systemic phenotype in young male C57Bl/6 mice. Two wks forced swimming (90 min twice daily) resulted in cardiac hypertrophy (22% increase in heart:body weight, P<0.

View Article and Find Full Text PDF

Objective: Approximately 20% of familial cases of amyotrophic lateral sclerosis (ALS) are caused by mutations in the gene encoding superoxide dismutase 1 (SOD1). Epidemiological data have identified traumatic brain injury (TBI) as an exogenous risk factor for ALS; however, the mechanisms by which TBI may worsen SOD1 ALS remain largely undefined.

Methods: We sought to determine whether repetitive TBI (rTBI) accelerates disease onset and progression in the transgenic SOD1 mouse ALS model, and whether loss of the primary regulator of axonal degeneration sterile alpha and TIR motif containing 1 (Sarm1) mitigates the histological and behavioral pathophysiology.

View Article and Find Full Text PDF

Aims: To date, bariatric surgery (BS) is the most effective long-term treatment for obesity, but weight regain (WR) is common. The very low-calorie ketogenic diet (VLCKD) is effective for weight loss and may influence gut microbiota (GM) composition, but it has been scarcely evaluated in post-bariatric patients. This study compared the efficacy and safety of a VLCKD in patients with WR post-bariatric surgery (BS+) and in bariatric surgery-naïve patients (BS-).

View Article and Find Full Text PDF

Edaravone Improves Motor Dysfunction Following Brachial Plexus Avulsion Injury in Rats.

ACS Chem Neurosci

January 2025

Department of Neurology, Multi-Omics Research Center for Brain Disorders,The First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, Hunan 421001, China.

Brachial plexus root avulsion (BPRA) is often caused by road collisions, leading to total loss of motor function in the upper limb. At present, effective treatment options remain limited. Edaravone (EDA), a substance that eliminates free radicals, exhibits numerous biological properties, including neuroprotective, antioxidant and anti-inflammatory effects.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!